In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Semaglutide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 4,624 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 1,224 (1,221 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 663 · 284 active124 more mention it but do not test it | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Semaglutide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weight | 969954105 | 834817 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Glycemic controlMetabolic and weight | 66866512 | 1,1171067491 |
|---|
| Adverse eventsWhole body | 7757723 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 345345 | 185185 |
|---|
| Cardiovascular eventsWhole body | 2672634 | 13313111 |
|---|
| Liver fat and liver functionMusculoskeletal | 17917441 | 1361279 |
|---|
| Heart functionCardiovascular | 67616 | 214198142 |
|---|
| LipidsMetabolic and weight | 1181171 | 14313733 |
|---|
| Kidney functionKidney and urinary | 1361351 | 1049932 |
|---|
| Blood pressureEndocrine and hormones | 9999 | 1201182 |
|---|
| Appetite and food intakeNervous system and cognition | 97952 | 1129517 |
|---|
| PharmacokineticsPharmacology | 93894 | 969231 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Semaglutide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: difference from placebo, in % | −2.54% Body weight change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 | −8.03% mean difference Dose studied: 3.0 mg once daily24 weeksn = 572023 |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in percentage points | −0.87 percentage points HbA1c change at 13 weeks Dose studied: maximum 14 mg once dailyn = 9,6502026 | −0.75 percentage points HbA1c difference |
| Liver fat and liver functionLiverCompared as: value in the arm that got the peptide, in % | 62.9% Resolution of steatohepatitis Placebo: 34.3% Dose studied: 2.4 mg once weekly72 weeks (interim analysis; planned 240 weeks)n = 8002025 | |
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | −3.9 mm Hg Systolic blood pressure difference Dose studied: 2.4 mg once weekly48 weeksn = 8032021 | |
| Exercise and physical functionCardiovascularCompared as: value in the arm that got the peptide, in m | 21.5 m 6-minute walk distance change Placebo: 1.2 m Dose studied: 2.4 mg once weekly52 weeksn = 5292023 | 488 m 6-minute walk distance 16 weeksn = 412024 |
| Body compositionMetabolic and weightCompared as: value in the arm that got the peptide, in % | −40% Visceral fat area change · semaglutide 2.4 mg Dose studied: 2.4 mg once weekly68 weeksn not reported2022 | |
| Appetite and food intakeMetabolic and weightCompared as: difference from placebo, in % | 35% Energy intake difference Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021 | −≈ 16% Ad libitum energy intake decrease · Shown as a change. The study reports a ad libitum energy intake decrease of this size. |
| Sex hormones and fertilityReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 35% natural pregnancy rate Dose studied: 1 mg once weekly16 weeksn = 802025 | |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in h | 145 to 165 h Half-life · semaglutide 2.4 mg Dose studied: 2.4 mg20 weeksn = 952021 | |
| Gastrointestinal motilityGastrointestinalCompared as: value in the arm that got the peptide, in min | 171 min Gastric half-emptying time Placebo: 118 min Dose studied: 1.0 mg once weekly12 weeksn = 202023 | 70 min Gastric emptying delay median · liraglutide, 5 weeks Placebo, 5 weeks: 4 min |
| Cardiovascular eventsCardiovascularCompared as: value in the arm that got the peptide, in days | 8 days RMST difference · SUSTAIN-6, semaglutide minus placebo n not reported2018 | 20 days RMST difference |
| Kidney functionKidney and urinaryCompared as: difference from placebo, in ml/min/1.73 m²/y | 0.87 mL/min/1.73 m²/y eGFR slope decline slowed Dose studied: 1.0 mgmedian follow-up 2.1 yearsn not reported2022 | 0.26 mL/min/1.73 m²/y eGFR slope decline slowed median follow-up 3.8 yearsn not reported |
−2.54%
Body weight change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
−8.03%
mean difference
Dose studied: 3.0 mg once daily24 weeksn = 572023
39%
Resolution of definite NASH
Placebo: 9%
Dose studied: 1·8 mg daily48 weeksn = 452016
−5 mm Hg 24-h systolic blood pressure change Dose studied: 1.8 mg/d12 weeksn = 272017 |
−2.87% Mean percent change in thigh muscle fat Placebo: 0.05% Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024 |
Dose studied: 1.8 mg and 3.0 mgn = 492014
69.2% Cumulative pregnancy rate Dose studied: 1.2 mg once daily12 weeksn = 282018 |
12.6 h
half-life · NN2211 s.c.
Dose studied: 1.25-12.5 microg/kgseven daysn not reported2002
Dose studied: 3·0 mg5 weeksn = 402017
n not reported2018
−0.87 percentage points
HbA1c change at 13 weeks
Dose studied: maximum 14 mg once dailyn = 9,6502026
−0.75 percentage points
HbA1c difference
Dose studied: 0.75 mg once daily12 weeksn not reported2004
62.9%
Resolution of steatohepatitis
Placebo: 34.3%
Dose studied: 2.4 mg once weekly72 weeks (interim analysis; planned 240 weeks)n = 8002025
39%
Resolution of definite NASH
Placebo: 9%
Dose studied: 1·8 mg daily48 weeksn = 452016
−3.9 mm Hg
Systolic blood pressure difference
Dose studied: 2.4 mg once weekly48 weeksn = 8032021
−5 mm Hg
24-h systolic blood pressure change
Dose studied: 1.8 mg/d12 weeksn = 272017
21.5 m
6-minute walk distance change
Placebo: 1.2 m
Dose studied: 2.4 mg once weekly52 weeksn = 5292023
488 m
6-minute walk distance
16 weeksn = 412024
−40%
Visceral fat area change · semaglutide 2.4 mg
Dose studied: 2.4 mg once weekly68 weeksn not reported2022
−2.87%
Mean percent change in thigh muscle fat
Placebo: 0.05%
Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024
35%
Energy intake difference
Dose studied: 2.4 mg once weekly (dose-escalated)20 weeksn = 722021
−≈ 16%
Ad libitum energy intake decrease · Shown as a change. The study reports a ad libitum energy intake decrease of this size.
Dose studied: 1.8 mg and 3.0 mgn = 492014
35%
natural pregnancy rate
Dose studied: 1 mg once weekly16 weeksn = 802025
69.2%
Cumulative pregnancy rate
Dose studied: 1.2 mg once daily12 weeksn = 282018
145 to 165 h
Half-life · semaglutide 2.4 mg
Dose studied: 2.4 mg20 weeksn = 952021
12.6 h
half-life · NN2211 s.c.
Dose studied: 1.25-12.5 microg/kgseven daysn not reported2002
171 min
Gastric half-emptying time
Placebo: 118 min
Dose studied: 1.0 mg once weekly12 weeksn = 202023
70 min
Gastric emptying delay median · liraglutide, 5 weeks
Placebo, 5 weeks: 4 min
Dose studied: 3·0 mg5 weeksn = 402017
8 days
RMST difference · SUSTAIN-6, semaglutide minus placebo
n not reported2018
20 days
RMST difference
n not reported2018
0.87 mL/min/1.73 m²/y
eGFR slope decline slowed
Dose studied: 1.0 mgmedian follow-up 2.1 yearsn not reported2022
0.26 mL/min/1.73 m²/y
eGFR slope decline slowed
median follow-up 3.8 yearsn not reported2022